课题基金 / 基金详情

项目摘要

项目成果

Juan Marugan的其他基金

相似基金

相关文献

中文摘要
翻译
NCATS早期翻译分支(ETB)拥有一个广泛而全面的计划,用于发现针对罕见疾病的候选药物和探索人类基因组功能的药理学工具。ETB开展研究,以了解推动基础研究发现转化为人类健康切实改善的基本原则。 新型小分子RXFP 3激动剂和拮抗剂将是阐明松弛素-3的功能以及其对RXFP 3受体的作用的有价值的工具。在此期间,项目团队致力于开发和表征筛选命中,以确定有效的RXFP 3调节剂。
英文摘要
The NCATS Early Translation Branch (ETB) hosts a broad and comprehensive program for the discovery of drug candidates directed towards rare diseases and pharmacological tools to probe the function of the human genome. ETB conducts research to understand the underlying principles driving the translation of basic research discoveries into tangible improvements in human health. Novel small molecule RXFP3 agonists and antagonists will be valuable tools to elucidate relaxin-3's function, as well as its actions at RXFP3 receptors. During this period, the project team has worked to develop and characterize screening hits to identify a potent RXFP3 modulator.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Small molecule agonists of the relaxin 1 receptor
Identification of Small Molecule that act on gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome
Kinetic High Throughput Screening for Agonists and Inhibitors of the TRPML1 Ion channel
HTS Assay for Identification of Compounds that Reduce PNC Prevalence
国内基金
海外基金
Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2020
  • 负责人:
    乔安娜
  • 依托单位: